A Barefoot Running Program For A College Lacrosse Player With Chronic Exertional Compartment Syndrome: A Case Report

Background and Purpose: Although barefoot running has been investigated for anterior and lateral exertional compartment syndrome, a specific barefoot running program aimed at altering running mechanics has not been determined for posterior exertional compartment syndrome for a college lacrosse player. The purpose of this case report was to examine the effects of adopting a forefoot running pattern through a barefoot running program in a 20-year-old college lacrosse player with posterior chronic exertional compartment syndrome (CECS) in conjunction with a comprehensive physical therapy program. Case description: The patient was a 20-year-old female college lacrosse player who presented to physical therapy with a 9-month history of bilateral, posterior lower leg pain, which was brought on by running on pavement, up hills, and longer than 5-10 minutes. The patient reported extreme tightness and throbbing in the posterior lower leg and numbness and tingling into the feet while running on pavement and long distance runs greater than 1 mile. The patient was seen 1-2x/week for twelve weeks. Outcomes: DF ROM improved from lacking 16° to lacking 8° on the right and lacking 12° to lacking 4° on the left. All hip and ankle strength improved from 4-4+/5 to 5/5 throughout. The LEFS improved from 9% disability to 5% disability. The patient’s running tolerance improved from 1 min shod to 12 min barefoot before experiencing tightness in her legs. Discussion: Barefoot running, in conjunction with manual therapy, lower extremity (LE) stretching, strengthening, and stabilization exercises was found to be effective at improving running tolerance for a female college lacrosse player. Future research should investigate the efficacy of barefoot running programs and appropriate timelines for progression in patients with posterior CECS

A Barefoot Running Program For A College Lacrosse Player With Chronic Exertional Compartment Syndrome: A Case Report

Barefoot running protocols have been effective in decreasing anterior and lateral chronic exertional compartment syndrome (CECS), but they have not been studied in patients with posterior CECS. Additionally, there is a lack of research that has investigated a barefoot running protocol in a college lacrosse athlete. The purpose of this case report was to examine the effects of adopting a forefoot strike pattern, through a barefoot running program, in a 20-year-old college lacrosse player with posterior chronic exertional compartment syndrome.https://dune.une.edu/pt_studcrposter/1134/thumbnail.jp

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

We reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in patients treated in the Italian compassionate-use program. 275 patients were included (202 male-73.5%, mean age: 57.4 years, 62 HIV-coinfected, 94 with recurrence of hepatitis C post-OLT). Forty-nine patients (17.8%) had Child-Pugh B, Genotype(G) distribution was: G1a:72 patients (26.2%), G1b:137 (49.8%); G3:40 (14.5%) and G4:26 (9.5%). Patients received DCV with sofosbuvir(SOF) (n\u2009=\u2009221, 129 with ribavirin(RBV) or with simeprevir (SMV) or asunaprevir (ASU) (n\u2009=\u200954, 19 with RBV) for up to 24 weeks. Logistic regression was used to identify baseline characteristics associated with sustained virological response at week 12 post-treatment (SVR12). Liver function changes between baseline and follow up were assessed in 228 patients. 240 patients achieved SVR12 (87.3%), post transplant and HIV co-infected patients were equally distributed among SVR and no SVR (35% vs 34.3%; p\u2009=\u20090.56 and 24.2% vs 11.4%, p\u2009=\u20090.13, respectively). SVR rate was significantly higher with the combination DCV\u2009+\u2009SOF compared with DCV\u2009+\u2009SIM or ASU (93.2% vs 63.0%, p\u2009<\u20090.0001). Bilirubin value (OR: 0.69, CI95%: 0.54-0.87, p\u2009=\u20090.002) and regimen containing SOF (OR: 9.99, CI95%: 4.09-24.40; p\u2009<\u20090.001) were independently related with SVR. Mean albumin and bilirubin values significantly improved between baseline and follow-up week 12. DCV-based antiviral therapy was well tolerated and resulted in a high SVR when combined with SOF either in pre-transplant and in OLT patients and in "difficult to treat" HCV genotypes. Regimens containing DCV in combination with NS3 protease inhibitors obtained suboptimal results